Center for Scientific Review; Notice of Closed Meetings
Published Date: 2/10/2026
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in March 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for cool science projects. If you’re involved in neuroscience, cancer nanotech, or nerve disease research, these reviews could impact your funding timeline and opportunities.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Closed virtual grant review meetings
The NIH Center for Scientific Review will hold closed virtual meetings on March 10-11, March 12-13, and March 13, 2026 to review and evaluate grant applications for study sections including Neurotoxicology and Alcohol, Cancer Nanotechnology, Guillain-Barré Syndrome/Chronic Inflammatory Demyelinating Polyneuropathy (GBS/CIDP), and Cell Structure and Function. If you are involved in those research areas, these reviews will affect decisions about who receives NIH research funding and could change your funding timeline or opportunities.
Applicant privacy and trade-secret protection
The meetings are closed to the public under Title 5 U.S.C. sections 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, commercial property, and personal information in grant applications. This protects applicants' confidential and personal data during the March 2026 virtual review meetings.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-02542, Information Collection: Invoice Submissions by Contractors for NRC Contracts/Orders
The Nuclear Regulatory Commission is renewing its rules for how contractors send in invoices for NRC contracts. If you work with the NRC, you’ll want to check the updated process and share your thoughts by March 12, 2026. This keeps payments smooth and on time, with no new costs expected.
Next: 2026-02544, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases (NIAID) is holding a private meeting from June 8-10, 2026, to review the skills and work of its researchers. This closed meeting affects NIAID staff and helps ensure top-notch science without sharing personal details publicly. No money changes are involved, but the meeting keeps research quality sharp and on track.